Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no study content or eligibility details were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoChange DetectedRevision: v3.4.0 updated to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedGlossary controls (Show glossary / Hide glossary) were added, and data fields were updated or renamed (Results First Posted, Last Update Posted, Last Update Submitted that Met QC Criteria). The labels 'Results First Posted (Estimated)' and 'No FEAR Act data' were removed, and the revision updated to v3.4.0.SummaryDifference0.4%

- Check33 days agoChange Detected- Revision label in the IPD Sharing Information section updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded a Locations section with Massachusetts site details and updated the revision to v3.3.3; removed the older Massachusetts Locations entry and the HHS Vulnerability Disclosure.SummaryDifference0.2%

- Check84 days agoChange DetectedPublication section wording updated to clarify that PubMed-listed publications are automatically populated and to note revision numbers (v3.3.2 vs v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.